NILA News
02/06/2023
SALSA Reintroduction in the Works
Having achieved a one-year delay in reimbursement cuts and data reporting, permanently addressing the flawed implementation of the Protecting Access to Medicare Act (PAMA) remains a top priority for NILA.
12/09/2022
NILA Urges House/Senate Leaders to Exclude VALID Act from Year-end Legislation
The letter was sent on behalf of the American Association of Bioanalysts (AAB) and the National Independent Laboratory Association (NILA).
12/08/2022
MPox (formerly Monkeypox) Public Health Emergency to End on January 31, 2023
Secretary of Health and Human Services (HHS) Xavier Becerra has issued a statement noting that HHS does not expect that it needs to renew the public health emergency (PHE) related to mpox (formerly monkeypox) when it ends on January 31, 2023.
07/06/2022
CMS Proposes New Rule for Rural Emergency Hospitals (REHs) and Critical Access Hospitals (CAHs)
CMS has published a new proposed rule intended to strengthen access to emergency care and additional outpatient services in rural communities by establishing the Conditions of Participation (CoP) for Rural Emergency Hospitals (REHs).
06/22/2022
NILA Applauds Introduction of the Saving Access to Lab Services Act
The National Independent Laboratory Association (NILA) applauds a bipartisan, bicameral group of legislators for working together to introduce the Saving Access to Laboratory Services Act (SALSA) to protect community and regional independent laboratories from drastic cuts to reimbursement in 2023 and future years. Learn More
06/14/2022
Lab Update: CDC Biosafety Town Hall on Medical Device Design - June 24
The U.S. Centers for Disease Control and Prevention (CDC) will host a virtual biosafety town hall on medical device design in collaboration with clinical and public health laboratory partners and instrument manufacturers on June 24, 2022, from 10:00 AM to 3:30 PM EDT. Learn More
06/13/2022
FDA Authorizes First COVID-19 Test to Identify Specific SARS-CoV-2 Lineages
The U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for the Laboratory Corporation of America (Labcorp) VirSeq SARS-CoV-2 NGS Test on the PacBio Sequel II sequencing system. Learn More
06/13/2022
Lab Advisory: CDC Publishes Monkeypox Virus PCR Testing Procedure
On June 6, 2022, CDC published a Real-Time PCR test procedure to detect Monkeypox virus. Learn More
05/23/2022
NILA one of nine parties to new CDC Memorandum of Understanding
NILA has joined with eight parties to a new CDC Memorandum of Understanding (MOU) for Diagnostic Surge Testing Capacity for Public Health Emergencies (PHEs). Parties to the MOU agree to collaborate on enhancing laboratory testing surge capacity outside of CDC and public health laboratories before and during PHEs. Learn More
05/23/2022
NILA Comments on Discussion Draft of VALID Act released May 17, 2022
On May 21, 2022, NILA submitted comments to Senator Patty Murray, chair of the Senate Committee on Health, Education, Labor & Pensions (HELP) and Senator Richard Burr, ranking member of the HELP Committee, on the discussion draft of the Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act of 2022. Learn More
NILA has signed a letter, along with 66 other health care organizations, to House and Senate leaders (Senators Schumer and McConnell and House members Pelosi and McCarthy) requesting Congress to restore funding for COVID-19 testing under the HRSA program. Learn More
03/17/2022
HRSA Program for COVID-19 Testing for the Uninsured
NILA has prepared background information and template letters for you to use to communicate to your Members of Congress the potentially severe disruptions in the Nation?s COVID response if funding for COVID-19 testing for uninsured patients is allowed to run out. Learn More
03/04/2022
Announcing the 2022 NILA Lab Leaders Forum and Mid-Year Meeting
Thank you to everyone who participated in and supported NILA?s Lab Leaders Forum and Mid-Year Meeting. Our return to an in-person meeting was a great success, and we look forward to seeing you again soon! Learn More
02/24/2022
FDA Update - Antibody (Serology) Testing for COVID-19: Information for Patients and Consumers
Antibodies are developed by the body in response to an infection or after vaccination. SARS-CoV-2 is the virus that causes COVID-19. SARS-CoV-2 antibody tests detect antibodies to the SARS-CoV-2 virus. Learn More
Archived News
Click here to see NILA's archived news.